Thank you for your interest in OGD2 Pharma.
Your message has been received. We will review your inquiry and respond as soon as possible.
Biopharma professional with 20+ years experience in drug development, CMC, regulatory affairs, and project leadership, combining scientific insight with strong team and program management.
Dr. Macy directs the Experimental Therapeutics Program at Children’s Hospital Colorado, the only early-phase paediatric oncology trial centre in the Rocky Mountain Region. She serves as institutional principal investigator for both the Pediatric Early Phase Clinical Trials Network (PEP-CTN) and the New Agents in Neuroblastoma Therapy (NANT) consortium. Her research focuses on relapsed/refractory neuroblastoma, with leadership roles across multiple COG and NANT trials including ANBL1821, ANBL2421, and a novel international biomarker platform study. She also serves as Medical Director for the Colorado Child Health Research Institute, with a particular focus on precision medicine and high-risk therapeutics.
Dr. Dubois is Director of Experimental Therapeutics at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, leading programmes to advance targeted therapies for paediatric cancers. He holds a Master of Science in Epidemiology from Harvard School of Public Health and trained in paediatric oncology at Dana-Farber/Boston Children’s Hospital. His translational research focuses on neuroblastoma and Ewing sarcoma, spanning Phase I–III clinical trials and biomarker discovery. He has served on the Children’s Oncology Group Neuroblastoma Steering Committee, ASCO Scientific Program Committee, and the FDA Paediatric Oncology Drugs Advisory Committee.
A pioneer in cancer immunotherapy and Academician of Academia Sinica, Dr. Yu led dinutuximab from preclinical development through FDA approval in 2015, which established anti-GD2 therapy as standard of care for high-risk neuroblastoma. She is Professor Emeritus of Pediatrics at UC San Diego and Distinguished Chair Professor at Chang Gung Memorial Hospital. A long-standing member of the COG Neuroblastoma Steering Committee, she holds multiple distinguished awards including the 2025 Lifetime Achievement Award from Advances in Neuroblastoma Research and the 2020 ASCO Pediatric Oncology Award.
Expert in integrating preclinical science, regulatory strategy, and intellectual property to support clinical translation and asset differentiation.
Biotech executive with 15+ years of experience across advanced therapies, focused on strategy, operations, and strategic partnerships.
Immunologist, entrepreneur, and investor with a long track record of translating immunology into medicines and building science-driven biotech companies.
